Thermo Fisher completes US$4B acquisition of Solventum’s purification & filtration business
Thermo Fisher will now serve adjacent high-growth industries that rely on ultra-pure water, including semiconductor, battery, and medical device manufacturing.
U.S.A – Thermo Fisher Scientific Inc., the global leader in serving science, has completed the acquisition of Solventum’s Purification & Filtration business for approximately US$4.0 billion in cash.
With the transaction now finalized, the acquired operations will be integrated into Thermo Fisher’s Life Sciences Solutions segment, now Thermo Fisher’s Filtration and Separation business.
The acquisition covers Solventum’s core Purification & Filtration business, which includes Bioprocessing Filtration, Healthcare and Industrial Filtration, as well as Membranes.
These capabilities significantly expand Thermo Fisher’s bioproduction portfolio with advanced filtration technologies designed to improve quality and efficiency across upstream and downstream workflows.
In addition to strengthening its bioprocessing presence, Thermo Fisher will now serve adjacent high-growth industries that rely on ultra-pure water, including semiconductor, battery, and medical device manufacturing.
For the full year 2025, the Filtration and Separation business is projected to generate approximately US$750 million in revenue.
Marc N. Casper, Chairman, President, and Chief Executive Officer of Thermo Fisher, welcomed the new employees, noting the strategic value of the acquisition.
“The addition of innovative filtration technologies is highly complementary and expands our bioprocessing portfolio to better serve the end-to-end needs of our pharma and biotech customers in this rapidly growing market. It also provides opportunities to broaden our reach in adjacent markets with attractive growth,” he said.
Financially, the newly integrated business is expected to deliver mid- to high-single-digit organic growth, with Thermo Fisher planning to leverage its Practical Process Improvement (PPI) Business System to drive margin expansion and achieve meaningful synergies.
In the first year of ownership, the deal is expected to dilute adjusted earnings per share (EPS) by US$0.06.
Thermo Fisher expects to achieve immediate cost savings by replacing Solventum’s expenses with lower operating costs, although one-time setup and financing costs will partially offset these.
By year five, Thermo Fisher expects to realize approximately US$125 million in adjusted operating income through revenue enhancements and cost savings.
In the long term, the transaction is projected to deliver compelling financial returns, with an anticipated internal rate of return of double digits.
Legal and financial advisors for Thermo Fisher included WilmerHale as principal deal counsel, Axinn and Latham & Watkins as regulatory counsel, Hogan Lovells as ex-U.S. counsel, and Wells Fargo as exclusive financial advisor.
Earlier this year, Thermo Fisher and Solventum agreed to exclude the Drinking Water Filtration business from the deal, reducing the purchase price by US$100 million. Solventum also committed to pay Thermo Fisher up to US$75 million upon the eventual sale of that business or within three years.
Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.
